|Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer|
Dose-Escalation Completed and Preliminary Antitumor Activity Observed
“SLC44A4 is an attractive target in prostate cancer and is present in
the majority of patients with both localized and metastatic disease,”
“It is encouraging to observe these preliminary data with ASG-5ME in
prostate cancer, a disease for which late-stage patients need additional
therapeutic options,” said
Phase 1 trial of ASG-5ME in metastatic castration-resistant prostate
cancer (CRPC) (Abstract #4568)
Key findings, presented by Dr.
The phase I trial is ongoing, with enrollment to two expansion cohorts in chemotherapy naïve and chemotherapy exposed CRPC patients planned.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50298288&lang=en